康斯坦斯队列中按年龄组(65岁以下或65岁以上)确定2型糖尿病患者首次接种流感疫苗的因素

IF 3.5 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-05 DOI:10.1080/21645515.2024.2437911
Sylvain Paquet, Virginie Ringa, Henri Panjo, Jeanne Sassenou, Marie Zins, Laurent Rigal
{"title":"康斯坦斯队列中按年龄组(65岁以下或65岁以上)确定2型糖尿病患者首次接种流感疫苗的因素","authors":"Sylvain Paquet, Virginie Ringa, Henri Panjo, Jeanne Sassenou, Marie Zins, Laurent Rigal","doi":"10.1080/21645515.2024.2437911","DOIUrl":null,"url":null,"abstract":"<p><p>Vaccine coverage against influenza is suboptimal among people with diabetes. Our principal objective was to study and compare the factors related to a first influenza vaccination in individuals with type 2 diabetes according to age group (<65 years and ≥ 65 years) and then to compare the older age group with diabetes to the general population of that age. This is a descriptive cross-sectional study within the French Constances cohort. The study populations were composed of people with type 2 diabetes and individuals without diabetes 65 years and older. Our variable of interest was the first reimbursement for a vaccine against influenza over the period from 2009 to 2019. We identified 2540 cohort members with type 2 diabetes (<65 years <i>n</i> = 1583; ≥65 years <i>n</i> = 957). The population without diabetes (≥65 years) comprised 18,364 individuals. The factors related to the first influenza vaccination differed significantly between the persons with diabetes younger than 65 years and those aged at least 65 years: age (OR = 1.01/OR = 0.89-<i>P-interaction</i><0.001), poor perceived health (OR = 1.24/OR = 0.79-<i>P-interaction</i> = 0.048), and indicators of diabetes treatment quality [at least 2 hbA1c assays/year (OR = 1.91/0 R = 0.90-<i>P-interaction</i><0.001), and blood pressure < 140/90 (OR = 1.24/OR = 0.90-<i>P-interaction</i> = 0.059)]. The only factor related to first influenza vaccination significantly different between individuals aged at least 65 years with and without diabetes was age (OR = 0.83/OR = 1.05-<i>P-interaction</i><0.001). This study shows that trials are now needed to test the effectiveness of age- and sex-specific messages to increase influenza vaccination coverage among people with diabetes.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2437911"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Factors determining first influenza vaccination among individuals with type 2 diabetes in the CONSTANCES cohort by age group (younger than 65 years or 65 and older).\",\"authors\":\"Sylvain Paquet, Virginie Ringa, Henri Panjo, Jeanne Sassenou, Marie Zins, Laurent Rigal\",\"doi\":\"10.1080/21645515.2024.2437911\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Vaccine coverage against influenza is suboptimal among people with diabetes. Our principal objective was to study and compare the factors related to a first influenza vaccination in individuals with type 2 diabetes according to age group (<65 years and ≥ 65 years) and then to compare the older age group with diabetes to the general population of that age. This is a descriptive cross-sectional study within the French Constances cohort. The study populations were composed of people with type 2 diabetes and individuals without diabetes 65 years and older. Our variable of interest was the first reimbursement for a vaccine against influenza over the period from 2009 to 2019. We identified 2540 cohort members with type 2 diabetes (<65 years <i>n</i> = 1583; ≥65 years <i>n</i> = 957). The population without diabetes (≥65 years) comprised 18,364 individuals. The factors related to the first influenza vaccination differed significantly between the persons with diabetes younger than 65 years and those aged at least 65 years: age (OR = 1.01/OR = 0.89-<i>P-interaction</i><0.001), poor perceived health (OR = 1.24/OR = 0.79-<i>P-interaction</i> = 0.048), and indicators of diabetes treatment quality [at least 2 hbA1c assays/year (OR = 1.91/0 R = 0.90-<i>P-interaction</i><0.001), and blood pressure < 140/90 (OR = 1.24/OR = 0.90-<i>P-interaction</i> = 0.059)]. The only factor related to first influenza vaccination significantly different between individuals aged at least 65 years with and without diabetes was age (OR = 0.83/OR = 1.05-<i>P-interaction</i><0.001). This study shows that trials are now needed to test the effectiveness of age- and sex-specific messages to increase influenza vaccination coverage among people with diabetes.</p>\",\"PeriodicalId\":49067,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":\"21 1\",\"pages\":\"2437911\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2024.2437911\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2437911","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

糖尿病患者的流感疫苗覆盖率不理想。我们的主要目的是研究和比较2型糖尿病患者按年龄组首次接种流感疫苗的相关因素(n = 1583;≥65岁n = 957)。无糖尿病人群(≥65岁)共18,364人。65岁以下的糖尿病患者与65岁以上的糖尿病患者首次接种流感疫苗的相关因素:年龄(OR = 1.01/OR = 0.89-P-interactionP-interaction = 0.048)和糖尿病治疗质量指标[每年至少2次hbA1c检测(OR = 1.91/0 R = 0.90-P-interactionP-interaction = 0.059)]。与首次流感疫苗接种相关的唯一因素是年龄(OR = 0.83/OR = 1.05- p相互作用)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Factors determining first influenza vaccination among individuals with type 2 diabetes in the CONSTANCES cohort by age group (younger than 65 years or 65 and older).

Vaccine coverage against influenza is suboptimal among people with diabetes. Our principal objective was to study and compare the factors related to a first influenza vaccination in individuals with type 2 diabetes according to age group (<65 years and ≥ 65 years) and then to compare the older age group with diabetes to the general population of that age. This is a descriptive cross-sectional study within the French Constances cohort. The study populations were composed of people with type 2 diabetes and individuals without diabetes 65 years and older. Our variable of interest was the first reimbursement for a vaccine against influenza over the period from 2009 to 2019. We identified 2540 cohort members with type 2 diabetes (<65 years n = 1583; ≥65 years n = 957). The population without diabetes (≥65 years) comprised 18,364 individuals. The factors related to the first influenza vaccination differed significantly between the persons with diabetes younger than 65 years and those aged at least 65 years: age (OR = 1.01/OR = 0.89-P-interaction<0.001), poor perceived health (OR = 1.24/OR = 0.79-P-interaction = 0.048), and indicators of diabetes treatment quality [at least 2 hbA1c assays/year (OR = 1.91/0 R = 0.90-P-interaction<0.001), and blood pressure < 140/90 (OR = 1.24/OR = 0.90-P-interaction = 0.059)]. The only factor related to first influenza vaccination significantly different between individuals aged at least 65 years with and without diabetes was age (OR = 0.83/OR = 1.05-P-interaction<0.001). This study shows that trials are now needed to test the effectiveness of age- and sex-specific messages to increase influenza vaccination coverage among people with diabetes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
CiteScore
7.90
自引率
8.30%
发文量
489
审稿时长
3-6 weeks
期刊介绍: (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信